AstraZeneca Made a $1.5 Billion Lung Cancer Bet, but Can Zegfrovy Strengthen its Oncology Growth?

AstraZeneca PLC (NYSE:AZN) is paying $600 million upfront to secure global rights to Zegfrovy from Dizal Pharmaceutical Co., ...

Abbott vs. Thermo Fisher: Which is the Better Investment, Diversification or Recovery?

Healthcare investors are often faced with a choice between companies that generate steady growth across diversified ...